# Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma

> **NCT06927128** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 45 (estimated)

## Conditions studied

- UTUC
- NAC

## Interventions

- **DRUG:** Gemcitabine, Cisplatin

## Key facts

- **NCT ID:** NCT06927128
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2026-05-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927128, "Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06927128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*